In the latest battle over access to medicines, Colombian authorities have decided to issue a compulsory license for a needed HIV treatment, a step that underscores ongoing friction between the pharmaceutical industry and cash-strapped governments around the world.
By issuing such a license, the Colombian government hopes to obtain lower-cost generic versions of an HIV medicine called dolutegravir, which is made by ViiV Healthcare, a company that specializes in HIV treatments and is largely controlled by GSK. The treatment is known commercially as Tivicay, or as Dovato when combined with other medicines.
“There should be a tendency to generate greater efficiencies in the health system with a view to guaranteeing the full enjoyment and access of Colombian population to the fundamental right to health, which constitutes a public interest that the Colombian state must pursue,” Colombian Health Minister Guillermo Alfonso Jaramillo explained in a 69-page declaration issued on Monday. The process, however, may take a few months before a license is issued.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect